Firebrick Pharma Limited (FRE.AX)
AUD 0.07
(-5.26%)
AUD 0.07
(-5.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -22.78 Thousand AUD | -2844.82% |
| 2023 | 830.00 AUD | -79.87% |
| 2022 | 4124.00 AUD | -99.02% |
| 2021 | 421.48 Thousand AUD | -17.14% |
| 2020 | 508.67 Thousand AUD | 112888.47% |
| 2019 | -451.00 AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | -856.38 Thousand AUD | -103278.31% |
| 2024 Q4 | 448.43 Thousand AUD | 0.0% |
| 2024 Q1 | 908.06 Thousand AUD | 19132.99% |
| 2024 Q2 | 904.45 Thousand AUD | -0.4% |
| 2024 Q3 | 448.43 Thousand AUD | -50.42% |
| 2023 Q1 | 11.27 Thousand AUD | -97.91% |
| 2023 FY | 830.00 AUD | -79.87% |
| 2023 Q4 | -4771.00 AUD | 0.0% |
| 2023 Q3 | - AUD | -100.0% |
| 2023 Q2 | 11.27 Thousand AUD | 0.0% |
| 2022 Q4 | 539.91 Thousand AUD | 0.0% |
| 2022 FY | 4124.00 AUD | -99.02% |
| 2022 Q3 | 539.91 Thousand AUD | 30576.93% |
| 2022 Q2 | 1760.00 AUD | -0.06% |
| 2022 Q1 | 1761.00 AUD | -99.17% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 FY | 421.48 Thousand AUD | -17.14% |
| 2021 Q4 | 211 Thousand AUD | 0.0% |
| 2021 Q3 | 211 Thousand AUD | 39761.65% |
| 2021 Q2 | -532.00 AUD | 0.0% |
| 2020 FY | 508.67 Thousand AUD | 112888.47% |
| 2019 FY | -451.00 AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Mayne Pharma Group Limited | 218.52 Million AUD | 100.01% |